Dapagliflozin Lowers Plasma Glucose Concentration and Improves β-Cell Function

BACKGROUND: β-Cell dysfunction is a core defect in T2DM, and chronic, sustained hyperglycemia has been implicated in progressive β-cell failure, ie, glucotoxicity. The aim of the present study was to examine the effect of lowering the plasma glucose concentration with dapagliflozin, a glucosuric age...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Endocrinol Metab
Egile Nagusiak: Merovci, Aurora, Mari, Andrea, Solis, Carolina, Xiong, Juan, Daniele, Giuseppe, Chavez-Velazquez, Alberto, Tripathy, Devjit, Urban McCarthy, Scheherezada, Abdul-Ghani, Muhammad, DeFronzo, Ralph A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Endocrine Society 2015
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4422889/
https://ncbi.nlm.nih.gov/pubmed/25710563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2014-3472
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak